Price history
¥1,268Latest-36.1%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview
Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
News
Key numbersShowing 8 of 19
PER
146.01How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.PBR
2.97How many times the company's net assets? Around 1x is generally considered a benchmark.ROE
2.0%Earning power. A figure above 10% is generally considered good.Dividend yield
0.0%The annual dividend as a percentage of the share price.Market capitalization
¥8.5bnShare price × number of shares. The value of the entire company.Equity ratio
79.0%The proportion of assets funded by money that does not have to be repaid.Operating margin
3.7%The percentage of revenue remaining from the company’s core business.Revenue growth (3 years)
0.8%The average annual growth in sales over the past three years.What to watch next
Plasma CVMおよびPAPの大型受注(約5.3億円規模報道)に伴う、納入・検収による売上計上と利益率改善
Second half of 2026 to 2027Impact HighLikelihood Medium
ミラー製造に係る機械装置投資の完了(着手2026年7月、完了予定2027年3月)による生産能力・品質安定の効果
Around March 2027Impact MediumLikelihood Medium
クラウドERP新基幹システム導入(2026年7月予定)による原価・在庫・購買統制の改善
2026年7月以降(効果は数四半期遅れ得る)Impact MediumLikelihood Low
第4世代放射光の新設/アップグレード(NanoTerasu稼働起点、欧州・アジア案件継続言及)による追加受注
Second half of 2026 to the medium termImpact MediumLikelihood Medium
What to watch next
Who owns itTop holders total 54.3%
Listed holders 54.3%Everyone else 45.7%
Tsumura Naofumi (津村 尚史)42.14%
大阪コンピュータ工業株式会社6.12%
The Master Trust Bank of Japan, Ltd. (Trust Account)1.36%
伊熊 譲1.02%
有馬 誠0.85%
内山 孝教0.84%
J.P. Morgan Securities Co., Ltd.0.55%
森 勇藏0.51%
2 other listed holders0.93%
| Holder | Ownership (%) |
|---|---|
| Tsumura Naofumi (津村 尚史) | 42.14 |
| 大阪コンピュータ工業株式会社 | 6.12 |
| The Master Trust Bank of Japan, Ltd. (Trust Account) | 1.36 |
| 伊熊 譲 | 1.02 |
| 有馬 誠 | 0.85 |
| 内山 孝教 | 0.84 |
| J.P. Morgan Securities Co., Ltd. | 0.55 |
| 森 勇藏 | 0.51 |
| 2 other listed holders | 0.93 |
This company's documents
Filings
Timely disclosures
- 2026-10-14Articles of Incorporation 2026/09/29
- 2026-09-29Notice Regarding the Issuance of New Shares as Restricted Stock-Based Compensation
- 2026-09-04Notification of Independent Officer Designation
- 2026-09-04Notice of Convocation of the 33rd Annual General Meeting of Shareholders: Information Provided Electronically
- 2026-09-04Notice of Convocation of the 33rd Annual General Meeting of Shareholders
- 2026-08-10Fiscal Year Ending June 2026 Financial Results Briefing Materials
- 2026-08-10Notice Regarding the Recording of an Income Tax Adjustment (Gain)
- 2026-08-10Notice Concerning the Formulation of a Medium-Term Management Plan
8 more
- 2026-08-10Financial Results for the Fiscal Year Ending June 2026 (Japanese GAAP) (Consolidated)
- 2026-07-13(Correction) Partial Correction to "Notice Concerning Changes to the Fiscal Year-End (End of Fiscal Year) and Partial Amendments to the Articles of Incorporation"
- 2026-07-10Notice Regarding the Change in the Fiscal Year-End and Partial Amendments to the Articles of Incorporation
- 2026-07-10Notice Regarding Revisions to Full-Year Consolidated Earnings Forecast
- 2026-06-29Notice Regarding an Order for Surface Processing and Polishing Equipment (Plasma CVM and PAP)
- 2026-05-14Notice Regarding the Recording of an Income Tax Adjustment (Gain)
- 2026-05-14Summary of Financial Results for the Third Quarter of the Fiscal Year Ending June 2026 (Japanese GAAP, Consolidated)
- 2026-03-11当社“OsakaMirror”大型受注のお知らせ
Threads
- 2026-10-14Plan to change the fiscal year-end from June to March
- 2026-09-29Introduction of a Restricted Stock Compensation Plan
- 2026-09-28Strengthening and expanding the operating base through two proprietary technology businesses
- 2026-09-28The Optical Business Drives Performance on Large-Scale Projects
- 2026-09-28Expansion of the CELLFLOAT System Using Rotary Suspension Culture Technology
- 2026-09-28Active Commitment to R&D
- 2026-09-28Declining Profitability and Impairment Losses in the Life Sciences and Equipment Development Business
- 2026-09-28Uncertainty in the overseas economy and volatility in foreign exchange and equity markets
64 more
- 2026-09-28Tokyo Stock Exchange Mothers Listing and Public Offering
- 2026-09-28Allocation of Proceeds to Construction of the Second Development Center and Equipment for the Optical Business
- 2026-09-28Expansion of Optical Business Production Capacity and Process Efficiency
- 2026-09-28Commercialization of the DM-150 Shape-Variable Mirror and Rollout of Next-Generation Systems
- 2026-09-28Expansion of Nanofabrication and Measurement Technologies into Other Industries, Including Semiconductors
- 2026-09-28Open Innovation Centered on a Cell Culture Center
- 2026-09-28Clinical research and clinical trials for elastic cartilage devices and development of a total system
- 2026-09-28Practical implementation of automated large-scale iPS cell passaging
- 2026-09-28Global Market Expansion for Synchrotron Radiation Facilities and Fourth-Generation Facilities
- 2026-09-28Dependence on sales of X-ray nanofocusing mirrors for synchrotron radiation facilities
- 2026-09-28Risk of Changes in Synchrotron Radiation Facilities and Government Research Policies
- 2026-09-28Risk of Regulatory Changes in Regenerative Medicine and Drug Discovery
- 2026-09-28Capacity, Quality and Delivery Risks at Outsourced Processing Suppliers
- 2026-09-28Risks related to product defects, litigation and damages
- 2026-09-28Risk of performance volatility due to long manufacturing lead times
- 2026-09-28Risk of intellectual property and know-how leakage and infringement of third-party rights
- 2026-09-28Information Leakage and Cyberattack Risks
- 2026-09-28No dividends while prioritizing retained earnings, with a policy of future dividends
- 2026-09-28Strengthening the Internal Management System
- 2026-09-28Strengthening technical consulting sales capabilities and talent
- 2026-09-28Fabless Manufacturing and Use of Partner Companies in the Life Sciences and Equipment Development Business
- 2026-09-28Development of new business fields in the Equipment Development Business
- 2026-09-28Change of Audit Firm
- 2026-09-28Company-wide performance: shift into the red and declining sales
- 2026-09-28Obsolescence of manufacturing technology and the emergence of technology offering comparable precision
- 2026-09-28Export Risks Arising from Political and Economic Conditions in Export Markets
- 2026-09-28Impairment due to a decline in the recoverability of fixed assets
- 2026-09-28Provision for contract losses on orders expected to incur losses
- 2026-09-28Delays in customer acceptance inspections and deferral of revenue recognition due to the spread of COVID-19
- 2026-09-28Strengthening Production and Quality Management Systems for Mass Production
- 2026-09-28Enhancing the Fairness and Transparency of Nomination and Compensation Procedures through the Nomination and Compensation Committee
- 2026-09-28Development of medical devices (drug-eluting and bone marrow mononuclear cell separation equipment)
- 2026-09-28Concentration of management resources on projects for China
- 2026-09-28Sales Collaboration, Manufacturing Efficiency and Advanced Development Through the Acquisition of 電子科学株式会社
- 2026-09-28Market expansion and new product development for 電子科学’s temperature-programmed desorption analyzers
- 2026-09-28Development and Provision of High-Value-Added Products Contributing to the SDGs and Carbon Neutrality
- 2026-09-28Sustainability promotion framework through management meetings and the Board of Directors
- 2026-09-28Securing and Developing Specialized Talent and Introducing New HR Systems
- 2026-09-28Targets for Increasing the Percentage of Women in Management Positions and the Parental Leave Uptake Rate
- 2026-09-28Management of Electricity Consumption and Energy-Related CO2 Emissions
- 2026-09-28Risk of failing to meet the Tokyo Stock Exchange Prime Market continued-listing criteria
- 2026-09-28Achieving the Long-Term Growth Strategy “Innovation2030”
- 2026-09-28Improving Operational Efficiency and Advancing Digital Transformation through Cloud ERP Implementation
- 2026-09-28Enhanced dialogue with stakeholders through IR videos and other channels
- 2026-09-28Competition for Highly Specialized Talent and Risk of R&D Talent Shortages
- 2026-09-28Risk of inadequate disclosure of non-financial information and KPIs
- 2026-09-28Review of Board Structure and Establishment of Titled Director Positions
- 2026-09-04Medium-Term Management Plan Targeting ¥4,200 Million in Sales and ¥855 Million in Operating Profit for the Fiscal Year Ending March 2029
- 2026-09-04Exploring M&A Opportunities in Optical Component and Automation Equipment Companies with Synergy Potential
- 2026-08-10Policy of treating improvement in the ordinary profit margin on sales as a key management metric
- 2026-08-10Significant Doubt About the Going Concern Assumption Arising From Operating Losses and Funding Measures
- 2026-05-14Recurring-Revenue Business Based on Consumables and Maintenance for Automated Cell Culture Equipment
- 2026-02-13Increase in Shares and Share Capital Through Exercise of Stock Acquisition Rights
- 2025-02-12Adoption of Accounting Standards for Income Taxes
- 2023-05-15Retirement of the Director and Head of the Administration Department and Change in Position of the Head of the Audit Office
- 2023-02-13Application of the Accounting Standards for Revenue Recognition and Fair Value Measurement
- 2023-02-13Change in the valuation method for products from the specific identification method to the moving average method
- 2023-02-13Reportable segmentation of Other businesses, including electronic science
- 2022-09-30Risks of Manufacturing Equipment Shutdowns and Natural Disasters
- 2020-09-30Dependence on the representative director and president
- 2020-09-30Human resources and business execution risks associated with a small organization
- 2020-09-30Selection for the 2020 Global Niche Top 100 Companies
- 2019-09-27Change in the treatment of cell culture center-related costs as company-wide expenses
- 2018-09-28Impairment of Idle Assets with No Expected Future Use